Status:
ACTIVE_NOT_RECRUITING
A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
Lead Sponsor:
National Jewish Health
Collaborating Sponsors:
University of California, Davis
Mayo Clinic
Conditions:
Hypersensitivity Pneumonitis
Eligibility:
All Genders
18-85 years
Brief Summary
Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood ca...
Detailed Description
Hypersensitivity pneumonitis is an immunologically mediated form of lung disease, resulting from inhalation exposure to a large variety of antigens. For unknown reasons, a subgroup of patients with HP...
Eligibility Criteria
Inclusion
- Diagnosis of chronic hypersensitivity pneumonitis
- Age 18 through 85 years.
- Diagnosis of chronic hypersensitivity pneumonitis by HRCT
- Able to understand and sign a written informed consent form.
- Able to understand the importance of adherence to the study protocol and willing to follow all study requirements
Exclusion
- Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study
- Known explanation for the interstitial lung disease
- Clinical diagnosis of any connective tissue disease
- Listed or expected to receive a lung transplant within 4 months from enrollment
- Pregnant women
Key Trial Info
Start Date :
January 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2025
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT04844359
Start Date
January 6 2021
End Date
July 31 2025
Last Update
May 14 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona
Tucson, Arizona, United States, 85719
2
University of California Davis
Sacramento, California, United States, 95817
3
National Jewish Health
Denver, Colorado, United States, 80206
4
University of Chicago
Chicago, Illinois, United States, 60637